NEW YORK (GenomeWeb News) – Oasis Diagnostics today announced it has licensed technology from two researchers for the development of saliva-based point-of-care diagnostics for Alzheimer's and Parkinson's diseases.
Financial and other terms of the deal were not disclosed.
Oasis, based in Vancouver, British Columbia, licensed the technology from Balwant Rai, program director and associate professor of aeronautic dentistry at Kansas State University, and Jasdeep Kaur, editor in chief of the Journal of Aeronautic Dentistry and executive editor of the Journal of Forensic Odontology and the Journal of Dental Education.
Oasis will develop point-of-care tests using eight proprietary biomarkers found in saliva for the diagnosis, prognosis, and monitoring of patients with Alzheimer's and/or Parkinson's. The company will develop the tests on its Verofy point-of-care platform, which uses immunochromatographic test strips.
The platform was originally developed for "roadside drugs of abuse testing" and is now also being developed for applications in stress management, diabetes, breast cancer, tuberculosis, and immune response to anthrax, according to Oasis' website.
The firm has developed technologies, it added, that have use in general wellness, global health, infectious diseases, DNA and RNA collection, nucleic acid testing, and protein characterization.
The Alzheimer's and Parkinson's test will detect specific concentrations of each of eight biomarkers to provide "a high degree of accuracy." For Parkinson's, the company added, as few as three biomarkers may be necessary on Verofy for diagnosis at an early stage.
Paul Slowey, the founder of Oasis, said the test will also have pharmacogenomic uses and "will facilitate earlier detection, earlier enrollment into available treatment protocols, and may be used as a tool to monitor the effectiveness of new therapies entering the market."